These novel treatments, Tirzepatide , represent a significant advancement in managing metabolic dysfunction and possibly related disorders. These drugs are classified as GLP-1 pathway activators , indicating they to mimic the endogenous GLP-1 peptide, boosting glucose release and reducing food intake. Despite Retatrutide every functions somewhat si